United States Infectious Disease Market Outlook to 2025

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$4995
Buy Report

Published: March 30, 2020 Report Code: GDMECC4879DB-ST

Select Item

GlobalData’s “United States Infectious Disease Market Outlook to 2025” is a comprehensive databook report, covering key market data on the United States Infectious Disease market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Chlamydia Trachomatis Tests, Clostridium difficile Tests, Cytomegalovirus (CMV) Tests, Hepatitis Tests, Human Immunodeficiency Virus (HIV) Tests, Human Papilloma Virus (HPV) Tests, Human T-Lymphotropic Virus (HTLV) Tests, Multi-parameter Chlamydia Trachomatis and Neisseria Gonorrhoeae NAATs, Multi-parameter HIV, Hepatitis B, and Hepatitis C Nucleic Acid Amplification Tests (NAATs), Mycobacterium Tuberculosis Tests, Neisseria Gonorrhoeae Tests and Treponema pallidum Tests.

The United States Infectious Disease Market report provides key information and data on:
• Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2015 to 2025.
• 2018 company share and distribution share data for Infectious Disease Market.
• Global corporate-level profiles of key companies operating within the United States Infectious Disease Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

United States Infectious Disease Tests is segmented as follows:

• Chlamydia Trachomatis Tests

• Clostridium difficile Tests

• Cytomegalovirus (CMV) Tests

• Hepatitis Tests

• Human Immunodeficiency Virus (HIV) Tests

• Human Papilloma Virus (HPV) Tests

• Human T-Lymphotropic Virus (HTLV) Tests

• Multi-parameter Chlamydia Trachomatis and Neisseria Gonorrhoeae NAATs

• Multi-parameter HIV, Hepatitis B, and Hepatitis C Nucleic Acid Amplification Tests (NAATs)

• Mycobacterium Tuberculosis Tests

• Neisseria Gonorrhoeae Tests

• Treponema pallidum Tests

Reasons to Buy

Key Reasons to Purchase – The United States Infectious Disease Market report helps you to develop:

• Business strategies by identifying the key market segments poised for strong growth in the future.

• Market-entry and market expansion strategies.

• Design competition strategies by identifying who-stands-where in the market.

• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

• Understand the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Key companies covered in the “United States Infectious Disease Market Outlook to 2025” report:
• Abbott Laboratories
• Hologic Inc
• Siemens Healthineers AG

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 6

2 Introduction 8

2.1 What Is This Report About? 8

2.2 Infectious Disease Market Segmentation 8

2.3 Definitions of Markets Covered in the Report 10

3 Infectious Disease Market, United States 17

3.1 Infectious Disease Market, United States, Revenue ($m), 2015-2025 17

3.1.1 Chlamydia Trachomatis Tests Market, United States, Revenue ($m), by Segment, 2015-2025 20

3.1.2 Clostridium difficile Tests Market, United States, Revenue ($m), by Segment, 2015-2025 22

3.1.3 Cytomegalovirus (CMV) Tests Market, United States, Revenue ($m), by Segment, 2015-2025 25

3.1.4 Hepatitis Tests Market, United States, Revenue ($m), by Segment, 2015-2025 28

3.1.5 Human Immunodeficiency Virus (HIV) Tests Market, United States, Revenue ($m), by Segment, 2015-2025 30

3.1.6 Human Papilloma Virus (HPV) Tests Market, United States, Revenue ($m), by Segment, 2015-2025 33

3.1.7 Human T-Lymphotropic Virus (HTLV) Tests Market, United States, Revenue ($m), by Segment, 2015-2025 35

3.1.8 Mycobacterium Tuberculosis Tests Market, United States, Revenue ($m), by Segment, 2015-2025 37

3.1.9 Neisseria Gonorrhoeae Tests Market, United States, Revenue ($m), by Segment, 2015-2025 39

3.1.10 Treponema pallidum Tests Market, United States, Revenue ($m), by Segment, 2015-2025 41

3.2 Infectious Disease Market, United States, Volume (Units), 2015-2025 44

3.2.1 Chlamydia Trachomatis Tests Market, United States, Volume (Units), by Segment, 2015-2025 49

3.2.2 Clostridium difficile Tests Market, United States, Volume (Units), by Segment, 2015-2025 51

3.2.3 Cytomegalovirus (CMV) Tests Market, United States, Volume (Units), by Segment, 2015-2025 54

3.2.4 Hepatitis Tests Market, United States, Volume (Units), by Segment, 2015-2025 56

3.2.5 Human Immunodeficiency Virus (HIV) Tests Market, United States, Volume (Units), by Segment, 2015-2025 58

3.2.6 Human Papilloma Virus (HPV) Tests Market, United States, Volume (Units), by Segment, 2015-2025 61

3.2.7 Human T-Lymphotropic Virus (HTLV) Tests Market, United States, Volume (Units), by Segment, 2015-2025 63

3.2.8 Mycobacterium Tuberculosis Tests Market, United States, Volume (Units), by Segment, 2015-2025 65

3.2.9 Neisseria Gonorrhoeae Tests Market, United States, Volume (Units), by Segment, 2015-2025 67

3.2.10 Treponema pallidum Tests Market, United States, Volume (Units), by Segment, 2015-2025 69

3.3 Infectious Disease Market, United States, Average Price ($), 2015-2025 72

3.4 Infectious Disease Market, United States, Distribution Share by Revenue ($m), 2018 78

3.5 Infectious Disease Market, United States, Company Share by Revenue ($m), 2018 79

4 Overview of Key Companies in United States, Infectious Disease Market 81

4.1 Abbott Laboratories 81

4.1.1 Company Overview 81

4.2 Hologic Inc 81

4.2.1 Company Overview 81

4.3 Siemens Healthineers AG 81

4.3.1 Company Overview 81

4.4 F. Hoffmann-La Roche Ltd 82

4.4.1 Company Overview 82

4.5 Danaher Corp 82

4.5.1 Company Overview 82

4.6 Qiagen NV 82

4.6.1 Company Overview 82

4.7 Ortho-Clinical Diagnostics Inc 82

4.7.1 Company Overview 82

4.8 Oxford Immunotec Ltd 83

4.8.1 Company Overview 83

4.9 Becton Dickinson and Co 83

4.9.1 Company Overview 83

4.10 Miraca Holdings Inc 83

4.10.1 Company Overview 83

4.11 Bio-Rad Laboratories Inc 83

4.11.1 Company Overview 83

4.12 Grifols SA 84

4.12.1 Company Overview 84

5 Infectious Disease Market Pipeline Products 85

6 Financial Deals Landscape 88

6.1 Acquisition 88

6.1.1 Prescient Medicine Acquires AutoGenomics 88

6.2 Debt Offerings 89

6.2.1 Eli Lilly Prices Public Offering of

1.7% Notes Due 2049 for USD1.1 Billion 89

6.2.2 Thermo Fisher Scientific Raises USD990 Million in Public Offering of

1.500% Notes Due 2039 91

6.2.3 Thermo Fisher Scientific Raises USD900 Million in Public Offering of

2.600% Notes Due 2029 94

6.2.4 Thermo Fisher Scientific Raises USD1.1 Billion in Public Offering of

1.875% Notes Due 2049 96

6.2.5 Thermo Fisher Scientific Raises USD880 Million in Public Offering of

0.500% Notes Due 2028 99

6.2.6 Thermo Fisher Scientific Raises USD990 Million in Public Offering of

0.875% Notes Due 2031 102

6.2.7 Thermo Fisher Scientific Raises USD880 Million in Public Offering of

0.125% Notes Due 2025 105

6.2.8 Becton Dickinson Raises USD669.7 Million in Public Offering of

0.174% Notes Due 2021 108

6.2.9 Becton Dickinson Raises USD669.7 Million in Public Offering of

1.208% Notes Due 2026 110

6.2.10 Becton Dickinson Raises USD893 Million in Public Offering of

0.632% Notes due 2023 112

6.2.11 Quest Diagnostics Raises USD500 Million in Public Offering of

4.2% Notes Due 2029 114

6.2.12 Eli Lilly Raises USD850 Million in Public Offering of

3.875% Bonds Due 2039 116

6.2.13 Eli Lilly Raises USD1.5 Billion in Public Offering of

3.95% Bonds Due 2049 118

6.2.14 Eli Lilly Raises USD1 Billion in Public Offering of

4.15% Bonds Due 2059 120

6.2.15 Eli Lilly Raises USD1.15 Billion in Public Offering of

3.375% Bonds Due 2029 122

6.3 Equity Offerings 124

6.3.1 Aethlon Medical Raises USD5 Million in Public Offering of Shares 124

6.3.2 Trovagene Raises USD5 Million in Private Placement of Shares and Warrants 126

6.3.3 Entasis Therapeutics to Raise up to USD20 Million in Public Offering of Shares 127

6.3.4 Accelerate Diagnostics Raises USD1 Million in Financing 128

6.3.5 GenMark Diagnostics to Raise up to USD35 Million in Public Offering of Shares 129

6.3.6 T2 Biosystems to Raise up to USD30 Million in Public offering of Shares 130

6.3.7 Trovagene Plans to Raise up to USD150 Million in Public Offering of Securities 131

6.3.8 Adaptive Biotech Raises USD345 Million in IPO of Shares 132

6.3.9 Aethlon Medical to Raise Up to USD1.25 Million Public Offering of Common Stock 134

6.3.10 Trovagene Raises USD3 Million in Private Placement of Shares upon Exercise of Warrants 135

6.3.11 Thermo Fisher Scientific Plans to Raise Funds through Public Offering of Securities 136

6.4 Merger 137

6.4.1 OpGen and Curetis to Merge 137

6.5 Partnerships 139

6.5.1 XCR Diagnostics Enters into Licensing Agreement with NeuMoDx Molecular 139

6.6 Private Equity 140

6.6.1 Trovagene to Raise USD1 Million in Private Placement of Shares and Warrants 140

6.7 Venture Financing 142

6.7.1 Phitonex Secures USD2 Million in Seed Funding 142

6.7.2 InDevR Raises USD7 Million in Series A Financing 143

6.7.3 Nuclein Raises USD0.4 Million in Venture Financing 144

6.7.4 Lucira Health (Diassess) Raises USD15 Million in Series B Financing 145

6.7.5 GeneCapture Raises USD0.04 Million in Venture Financing 146

6.7.6 Nuclease Probe Technologies Raises USD0.5 Million in Financing 147

7 Appendix 148

7.1 Research Methodology 149

7.1.1 Coverage 149

7.1.2 Secondary Research 149

7.1.3 Primary Research 150

7.1.4 Market Modeling and Forecasting 151

7.1.5 Company Share Analysis 152

7.1.6 Distribution Share Analysis 153

7.1.7 Benchmarking 153

7.2 GlobalData Consulting 153

7.3 Contact Us 154

7.4 Disclaimer 154

Table

1.1 List of Tables

Table 1: Infectious Disease Market, United States, Revenue ($m), USD Constant, 2015-2020 22

Table 2: Infectious Disease Market, United States, Revenue ($m), USD Constant, 2021-2025 23

Table 3: Chlamydia Trachomatis Tests Market, United States, Revenue ($m), USD Constant, 2015-2020 25

Table 4: Chlamydia Trachomatis Tests Market, United States, Revenue ($m), USD Constant, 2021-2025 25

Table 5: Clostridium difficile Tests Market, United States, Revenue ($m), USD Constant, 2015-2020 27

Table 6: Clostridium difficile Tests Market, United States, Revenue ($m), USD Constant, 2021-2025 28

Table 7: Cytomegalovirus (CMV) Tests Market, United States, Revenue ($m), USD Constant, 2015-2020 30

Table 8: Cytomegalovirus (CMV) Tests Market, United States, Revenue ($m), USD Constant, 2021-2025 31

Table 9: Hepatitis Tests Market, United States, Revenue ($m), USD Constant, 2015-2020 33

Table 10: Hepatitis Tests Market, United States, Revenue ($m), USD Constant, 2021-2025 33

Table 11: Human Immunodeficiency Virus (HIV) Tests Market, United States, Revenue ($m), USD Constant, 2015-2020 35

Table 12: Human Immunodeficiency Virus (HIV) Tests Market, United States, Revenue ($m), USD Constant, 2021-2025 36

Table 13: Human Papilloma Virus (HPV) Tests Market, United States, Revenue ($m), USD Constant, 2015-2020 38

Table 14: Human Papilloma Virus (HPV) Tests Market, United States, Revenue ($m), USD Constant, 2021-2025 38

Table 15: Human T-Lymphotropic Virus (HTLV) Tests Market, United States, Revenue ($m), USD Constant, 2015-2020 40

Table 16: Human T-Lymphotropic Virus (HTLV) Tests Market, United States, Revenue ($m), USD Constant, 2021-2025 40

Table 17: Mycobacterium Tuberculosis Tests Market, United States, Revenue ($m), USD Constant, 2015-2020 42

Table 18: Mycobacterium Tuberculosis Tests Market, United States, Revenue ($m), USD Constant, 2021-2025 42

Table 19: Neisseria Gonorrhoeae Tests Market, United States, Revenue ($m), USD Constant, 2015-2020 44

Table 20: Neisseria Gonorrhoeae Tests Market, United States, Revenue ($m), USD Constant, 2021-2025 44

Table 21: Treponema pallidum Tests Market, United States, Revenue ($m), USD Constant, 2015-2020 46

Table 22: Treponema pallidum Tests Market, United States, Revenue ($m), USD Constant, 2021-2025 47

Table 23: Infectious Disease Market, United States, Volume (Units), 2015-2020 49

Table 24: Infectious Disease Market, United States, Volume (Units), 2021-2025 51

Table 25: Chlamydia Trachomatis Tests Market, United States, Volume (Units), 2015-2020 54

Table 26: Chlamydia Trachomatis Tests Market, United States, Volume (Units), 2021-2025 54

Table 27: Clostridium difficile Tests Market, United States, Volume (Units), 2015-2020 56

Table 28: Clostridium difficile Tests Market, United States, Volume (Units), 2021-2025 57

Table 29: Cytomegalovirus (CMV) Tests Market, United States, Volume (Units), 2015-2020 59

Table 30: Cytomegalovirus (CMV) Tests Market, United States, Volume (Units), 2021-2025 59

Table 31: Hepatitis Tests Market, United States, Volume (Units), 2015-2020 61

Table 32: Hepatitis Tests Market, United States, Volume (Units), 2021-2025 61

Table 33: Human Immunodeficiency Virus (HIV) Tests Market, United States, Volume (Units), 2015-2020 63

Table 34: Human Immunodeficiency Virus (HIV) Tests Market, United States, Volume (Units), 2021-2025 64

Table 35: Human Papilloma Virus (HPV) Tests Market, United States, Volume (Units), 2015-2020 66

Table 36: Human Papilloma Virus (HPV) Tests Market, United States, Volume (Units), 2021-2025 66

Table 37: Human T-Lymphotropic Virus (HTLV) Tests Market, United States, Volume (Units), 2015-2020 68

Table 38: Human T-Lymphotropic Virus (HTLV) Tests Market, United States, Volume (Units), 2021-2025 68

Table 39: Mycobacterium Tuberculosis Tests Market, United States, Volume (Units), 2015-2020 70

Table 40: Mycobacterium Tuberculosis Tests Market, United States, Volume (Units), 2021-2025 70

Table 41: Neisseria Gonorrhoeae Tests Market, United States, Volume (Units), 2015-2020 72

Table 42: Neisseria Gonorrhoeae Tests Market, United States, Volume (Units), 2021-2025 72

Table 43: Treponema pallidum Tests Market, United States, Volume (Units), 2015-2020 74

Table 44: Treponema pallidum Tests Market, United States, Volume (Units), 2021-2025 75

Table 45: Infectious Disease Market, United States, Average Price ($), 2015-2020 76

Table 46: Infectious Disease Market, United States, Average Price ($), 2021-2025 79

Table 47: Infectious Disease Market, United States, Distribution Share by Revenue ($m), USD Constant, 2018 82

Table 48: Infectious Disease Market, United States, Company Share by Revenue ($m), USD Constant, 2018 84

Table 49: Infectious Disease Market Pipeline Products 89

Table 50: Prescient Medicine Acquires AutoGenomics 92

Table 51: Eli Lilly Prices Public Offering of 1.7% Notes Due 2049 for USD1.1 Billion 93

Table 52: Thermo Fisher Scientific Raises USD990 Million in Public Offering of 1.500% Notes Due 2039 95

Table 53: Thermo Fisher Scientific Raises USD900 Million in Public Offering of 2.600% Notes Due 2029 98

Table 54: Thermo Fisher Scientific Raises USD1.1 Billion in Public Offering of 1.875% Notes Due 2049 100

Table 55: Thermo Fisher Scientific Raises USD880 Million in Public Offering of 0.500% Notes Due 2028 103

Table 56: Thermo Fisher Scientific Raises USD990 Million in Public Offering of 0.875% Notes Due 2031 106

Table 57: Thermo Fisher Scientific Raises USD880 Million in Public Offering of 0.125% Notes Due 2025 109

Table 58: Becton Dickinson Raises USD669.7 Million in Public Offering of 0.174% Notes Due 2021 112

Table 59: Becton Dickinson Raises USD669.7 Million in Public Offering of 1.208% Notes Due 2026 114

Table 60: Becton Dickinson Raises USD893 Million in Public Offering of 0.632% Notes due 2023 116

Table 61: Quest Diagnostics Raises USD500 Million in Public Offering of 4.2% Notes Due 2029 118

Table 62: Eli Lilly Raises USD850 Million in Public Offering of 3.875% Bonds Due 2039 120

Table 63: Eli Lilly Raises USD1.5 Billion in Public Offering of 3.95% Bonds Due 2049 122

Table 64: Eli Lilly Raises USD1 Billion in Public Offering of 4.15% Bonds Due 2059 124

Table 65: Eli Lilly Raises USD1.15 Billion in Public Offering of 3.375% Bonds Due 2029 126

Table 66: Aethlon Medical Raises USD5 Million in Public Offering of Shares 128

Table 67: Trovagene Raises USD5 Million in Private Placement of Shares and Warrants 130

Table 68: Entasis Therapeutics to Raise up to USD20 Million in Public Offering of Shares 131

Table 69: Accelerate Diagnostics Raises USD1 Million in Financing 132

Table 70: GenMark Diagnostics to Raise up to USD35 Million in Public Offering of Shares 133

Table 71: T2 Biosystems to Raise up to USD30 Million in Public offering of Shares 134

Table 72: Trovagene Plans to Raise up to USD150 Million in Public Offering of Securities 135

Table 73: Adaptive Biotech Raises USD345 Million in IPO of Shares 136

Table 74: Aethlon Medical to Raise Up to USD1.25 Million Public Offering of Common Stock 138

Table 75: Trovagene Raises USD3 Million in Private Placement of Shares upon Exercise of Warrants 139

Table 76: Thermo Fisher Scientific Plans to Raise Funds through Public Offering of Securities 140

Table 77: OpGen and Curetis to Merge 141

Table 78: XCR Diagnostics Enters into Licensing Agreement with NeuMoDx Molecular 143

Table 79: Trovagene to Raise USD1 Million in Private Placement of Shares and Warrants 144

Table 80: Phitonex Secures USD2 Million in Seed Funding 146

Table 81: InDevR Raises USD7 Million in Series A Financing 147

Table 82: Nuclein Raises USD0.4 Million in Venture Financing 148

Table 83: Lucira Health (Diassess) Raises USD15 Million in Series B Financing 149

Table 84: GeneCapture Raises USD0.04 Million in Venture Financing 150

Table 85: Nuclease Probe Technologies Raises USD0.5 Million in Financing 151

Table 86: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country 317

Figures

1.2 List of Figures

Figure 1: Infectious Disease Market, United States, Revenue ($m), USD Constant, 2015-2025 21

Figure 2: Chlamydia Trachomatis Tests Market, United States, Revenue ($m), USD Constant, 2015-2025 24

Figure 3: Clostridium difficile Tests Market, United States, Revenue ($m), USD Constant, 2015-2025 26

Figure 4: Cytomegalovirus (CMV) Tests Market, United States, Revenue ($m), USD Constant, 2015-2025 29

Figure 5: Hepatitis Tests Market, United States, Revenue ($m), USD Constant, 2015-2025 32

Figure 6: Human Immunodeficiency Virus (HIV) Tests Market, United States, Revenue ($m), USD Constant, 2015-2025 34

Figure 7: Human Papilloma Virus (HPV) Tests Market, United States, Revenue ($m), USD Constant, 2015-2025 37

Figure 8: Human T-Lymphotropic Virus (HTLV) Tests Market, United States, Revenue ($m), USD Constant, 2015-2025 39

Figure 9: Mycobacterium Tuberculosis Tests Market, United States, Revenue ($m), USD Constant, 2015-2025 41

Figure 10: Neisseria Gonorrhoeae Tests Market, United States, Revenue ($m), USD Constant, 2015-2025 43

Figure 11: Treponema pallidum Tests Market, United States, Revenue ($m), USD Constant, 2015-2025 45

Figure 12: Infectious Disease Market, United States, Volume (Units), 2015-2025 48

Figure 13: Chlamydia Trachomatis Tests Market, United States, Volume (Units), 2015-2025 53

Figure 14: Clostridium difficile Tests Market, United States, Volume (Units), 2015-2025 55

Figure 15: Cytomegalovirus (CMV) Tests Market, United States, Volume (Units), 2015-2025 58

Figure 16: Hepatitis Tests Market, United States, Volume (Units), 2015-2025 60

Figure 17: Human Immunodeficiency Virus (HIV) Tests Market, United States, Volume (Units), 2015-2025 62

Figure 18: Human Papilloma Virus (HPV) Tests Market, United States, Volume (Units), 2015-2025 65

Figure 19: Human T-Lymphotropic Virus (HTLV) Tests Market, United States, Volume (Units), 2015-2025 67

Figure 20: Mycobacterium Tuberculosis Tests Market, United States, Volume (Units), 2015-2025 69

Figure 21: Neisseria Gonorrhoeae Tests Market, United States, Volume (Units), 2015-2025 71

Figure 22: Treponema pallidum Tests Market, United States, Volume (Units), 2015-2025 73

Figure 23: Infectious Disease Market, United States, Company Share (%) 2018 83

Frequently asked questions

United States Infectious Disease Market Outlook to 2025 standard reports
Currency USD
$4,995

Can be used by individual purchaser only

Most Popular
$9,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$14,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more In Vitro Diagnostics reports
Medical Devices
New
PTA Peripheral DCB Catheters Pipeline by Development Stages, Segments, Region…
$4,000 | March 2024
Medical Devices
New
PCR Systems Market Size by Segments, Share, Regulatory, Reimbursement, Installed…
$7,500 | March 2024
Medical Devices
New
Immunochemistry Analyzers Market Size by Segments, Share, Regulatory, Reimbursement, Installed…
$7,500 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at United States Infectious Disease Market Outlook to 2025 in real time.

  • Access a live United States Infectious Disease Market Outlook to 2025 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more